Clinical Trial Update: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of peginterferon lambda-1a plus ribavirin plus daclatasvir in Hepatitis C genotype 1b patients (treatment-naïve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Peginterferon lambda-1a (peginterferon lambda-1a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED